RxDoctor Payments Data

Jared Lee, MD

Pulmonary Disease · Frisco, TXNPI 1972949352

Payments from drug & device makers

$6,749in general payments, 2019–2025

Across 71 payments — averaging $95.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$5K
  • Johnson & Johnson$511
  • Pulmonx Corporation$267
  • Actelion Pharmaceuticals US, Inc.$265
  • GSK$201
  • Boehringer Ingelheim$198
  • plus $716 from 15 others

What the payments were for

  • Speaking & faculty fees$1,50022%
  • Travel & lodging$3896%
  • Food & beverage$1,86028%
  • Education$3,00044%

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,749 in reported general payments places this provider in the 65th percentile of 904 pulmonary disease providers in Texas.

See all pulmonary disease providers in Texas

Medicare billing

Part B allowed, 2024
$442,881
Medicare patients
648
Services billed
3,815

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate35$456,614
Trelegy ElliptaFluticasone/Umeclidin/Vilanter192$141,186
Breo ElliptaFluticasone/Vilanterol44$28,130
Stiolto RespimatTiotropium Br/Olodaterol Hcl33$21,149
Spiriva RespimatTiotropium Bromide17$20,981
SymbicortBudesonide/Formoterol Fumarate25$11,649
Wixela InhubFluticasone Propion/Salmeterol22$3,845
BreynaBudesonide/Formoterol Fumarate15$3,226
Azithromycin116$1,957
Albuterol Sulfate HfaAlbuterol Sulfate46$1,945
Ipratropium Bromide34$1,529
Montelukast Sodium66$951
Prednisone152$791
Pantoprazole Sodium37$533
Famotidine29$464

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat$198$498,74485 claims
GSKTrelegy Ellipta, Breo Ellipta$201$169,316236 claims
AstraZenecaSymbicort$27$11,64925 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 904 pulmonary disease providers in Texas.

Other pulmonary disease in Frisco

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →